Drugs / GLR1075
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07851688 | Oct 2026 → Dec 2028 expected | — | Gan & Lee Pharmaceuticals. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-09-21 | Gan and Lee Pharmaceuticals, USA | Regulatory Gan & Lee Pharmaceuticals Enters Recombinant Human Albumin Drug Research Field; GLR1075 Injection Receives Clinical Trial Approval ganlee.com ↗
Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee Pharmaceuticals"; stock code: 603087.SH) announced that its independently developed recombinant human albumin GLR1075 Injection has officially received Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-09-21 | Gan and Lee Pharmaceuticals, USA | Gan & Lee Pharmaceuticals Enters Recombinant Human Albumin Drug Research Field; GLR1075 Injection Receives Clinical Trial Approval ganlee.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLR1075 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07851688 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human albumin injection” NCT07851688 ↗ |
| Route | Intravenous | “recombinant human albumin injection single dose or multiple doses of intravenous infusion” NCT07851688 ↗ |